Oral LY4268989 compared with placebo in moderate to severe ulcerative colitis
Tests whether oral LY4268989 helps adults with active ulcerative colitis, a long-term bowel disease.
Plain-language title generated from the registry record
Registry title: LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Key facts
- Where
- Anaheim, Boise, Charleston, Chicago, Colorado Springs, Daytona Beach, Denver, Des Plaines, Folsom, Fort Worth, Garland, Greenville, Hamden, Hilliard, Houston, Idaho Falls, Jackson, Kissimmee, Lakewood, Lakewood Rch, Las Vegas, Louisville, Mandeville, Mansfield, Moorestown, New Albany, New Brunswick, Norfolk, Orlando, Phoenix, Portland, Rochester, San Antonio, San Marcos, Scottsdale, Seattle, Sioux Falls, Spokane, Springboro, Springfield, St Louis, Stony Brook, Tacoma, Temple City, Tyler, Victorville, Westlake, Wilmington, and Wyoming, United StatesSee the 52 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07415044, who can take part
Where in United States
- Clinnova ResearchAnaheim, United StatesTaking people
- Treasure Valley Medical ResearchBoise, United StatesTaking people
- Medical University of South CarolinaCharleston, United StatesNot yet recruiting
- Northwestern UniversityChicago, United StatesNot yet recruiting
- Rush University Medical CenterChicago, United StatesNot yet recruiting
- Peak Gastroenterology AssociatesColorado Springs, United StatesTaking people
- K2 Medical Research - Daytona BeachDaytona Beach, United StatesTaking people
- Advanced Research Institute - DenverDenver, United StatesNo longer taking part
- Midwest Digestive Health & NutritionDes Plaines, United StatesTaking people
- GMC Clinical ResearchFolsom, United StatesTaking people
- GI Alliance - Fort WorthFort Worth, United StatesTaking people
- GI Alliance - GarlandGarland, United StatesTaking people
- Carolina Digestive Diseases and Endoscopy CenterGreenville, United StatesTaking people
- Medical Research Center of ConnecticutHamden, United StatesNot yet recruiting
- Ohio State UniversityHilliard, United StatesNot yet recruiting
- Integrity Advanced TherapeuticsHouston, United StatesTaking people
- Grand Teton Research GroupIdaho Falls, United StatesTaking people
- Skyline Gastroenterology of West TennesseeJackson, United StatesTaking people
- Clinical Research of OsceolaKissimmee, United StatesTaking people
- Rocky Mountain Gastroenterology Associates - LakewoodLakewood, United StatesTaking people
- Florida Research InstituteLakewood Rch, United StatesTaking people
- Digestive Disease Specialists - Las Vegas - Crimson Canyon DriveLas Vegas, United StatesTaking people
- Gastroenterology Health PartnersLouisville, United StatesTaking people
- GI Alliance - Gastro Group and Endocenter - MandevilleMandeville, United StatesTaking people
- GI Alliance - MansfieldMansfield, United StatesTaking people
- Virtua Health & Wellness Center - MoorestownMoorestown, United StatesNot yet recruiting
- Gastroenterology Health PartnersNew Albany, United StatesTaking people
- Saint Peter's University HospitalNew Brunswick, United StatesTaking people
- Eximia Research-VA, LLCNorfolk, United StatesTaking people
- AdventHealth OrlandoOrlando, United StatesNot yet recruiting
- Valleywise Health Medical CenterPhoenix, United StatesTaking people
- The Oregon ClinicPortland, United StatesTaking people
- Mayo Clinic in Rochester, MinnesotaRochester, United StatesNot yet recruiting
- Southern Star Research InstituteSan Antonio, United StatesTaking people
- GI Alliance - San MarcosSan Marcos, United StatesTaking people
- One of a Kind Clinical Research CenterScottsdale, United StatesTaking people
- Swedish Medical CenterSeattle, United StatesNot yet recruiting
- Sanford USD Medical CenterSioux Falls, United StatesTaking people
- Principle Research SolutionsSpokane, United StatesTaking people
- Providence Sacred Heart Medical Center & Children's HospitalSpokane, United StatesTaking people
- DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - SpringboroSpringboro, United StatesTaking people
- Springfield Clinic - FirstSpringfield, United StatesTaking people
- KAD Clinical ResearchSt Louis, United StatesTaking people
- Specialists in GastroenterologySt Louis, United StatesTaking people
- Stony Brook UniversityStony Brook, United StatesNot yet recruiting
- Washington Gastroenterology - TacomaTacoma, United StatesTaking people
- Om Research LLCTemple City, United StatesTaking people
- Tyler Research InstituteTyler, United StatesTaking people
- Om Research, LLCVictorville, United StatesTaking people
- Gastro Intestinal Research Institute of Northern Ohio, LLCWestlake, United StatesTaking people
- Wilmington Health, PLLCWilmington, United StatesTaking people
- Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research CenterWyoming, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07415044
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.Read full original descriptionShow less
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.
The study will last up to approximately 108 weeks, excluding screening.
Inclusion: Have had an established diagnosis of ulcerative colitis (UC) for ≥3 months prior to randomization, which includes endoscopic evidence of UC; Have moderately to severely active UC defined by a Modified Mayo Score (mMS) of 5 to 9 with an Endoscopic Score (ES)≥2 confirmed by central reader and rectal bleeding (RB)≥1; Have evidence of UC extending proximal to the rectum; Have documented evidence of having had a surveillance colonoscopy within 1 year, or according to local guidelines, to evaluate for polyps, dysplasia, or malignancy, prior to randomization, if the participant has a history of UC symptoms for more than 8 years; Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators). Participants with inadequate response to vedolizumab are excluded; Must meet contraception requirements.
Exclusion: Have had or will need bowel resection or intestinal or intra-abdominal surgery; Have any prior or current evidence of cancer gastrointestinal (GI) tract, or specified lesions with increased risk of GI malignancies; Have a current diagnosis of; Crohn's disease; Inflammatory Bowel Disease (IBD unclassified) (formerly known as indeterminate colitis), or; primary sclerosing cholangitis; Have an inherited immunodeficiency syndrome or known monogenic cause of UC-like colonic inflammation; Have a diagnosis or history of malignant disease within 5 years prior to randomization; Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic.